MapLight Therapeutics entered into a sales agreement with Leerink Partners to establish an at-the-market (ATM) offering program. The company may sell up to $100 million of its common stock from time to time, with Leerink acting as the sales agent for a commission of up to 3.0%.
MapLight Therapeutics reported a significant increase in net loss to $172.5 million for the nine months ended September 30, 2026, compared to $81.6 million in the prior year, primarily driven by a doubling of research and development expenses. The company strengthened its balance sheet through a private placement in the third quarter of 2026, yielding $140.1 million in net proceeds.
MapLight Therapeutics reported Q3 2026 financial results and provided a clinical pipeline update, including plans for its Phase 3 ZEPHYR-2 trial in schizophrenia. The company ended the quarter with $463.4 million in cash, which is expected to fund operations through 2028 and key clinical readouts.
Term
Q3 2026
“Following the positive results from our ZEPHYR study, we are focused on advancing ML-007C-MA into an additional registrational study and positioning it to compete in the broader antipsychotic market.”
Chris Kroeger, Co-Founder and Chief Executive Officer
“We believe that the strength and consistency of the ZEPHYR efficacy results, combined with the ease-of-use tolerability profile, provide a solid foundation for our planned Phase 3 trial and reinforce our confidence in the potential of ML-007C-MA in schizophrenia.”
Chris Kroeger, Co-Founder and Chief Executive Officer
Anatol Kreitzer, Chief Discovery Officer, sold 12,248 shares of MapLight Therapeutics, Inc. at $7.84 a share, worth $96K in total on Oct 15, 2026. Shares held after the trade: 168,678 (-6.8%).
MapLight Therapeutics CMO Erin Pennock Foff Sells $124K of Stock
Erin Pennock Foff, CMO, sold 15,355 shares of MapLight Therapeutics, Inc. at $8.08 a share, worth $124K in total on Oct 15, 2026. Shares held after the trade: 296,906 (-4.9%).
MapLight Therapeutics General Counsel Kristopher Hanson Sells $72.9K of Stock
Kristopher Hanson, General Counsel, sold 9,020 shares of MapLight Therapeutics, Inc. at $8.08 a share, worth $72.9K in total on Oct 15, 2026. Shares held after the trade: 128,024 (-6.6%).
MapLight Therapeutics CAO and Interim CFO Jonathan Gillis Sells $82.1K of Stock
Jonathan Gillis, CAO and Interim CFO, sold 10,167 shares of MapLight Therapeutics, Inc. at $8.08 a share, worth $82.1K in total on Oct 15, 2026. Shares held after the trade: 142,315 (-6.7%).
MapLight Therapeutics CSO James Woodruff Lillie Sells $93K of Stock
James Woodruff Lillie, CSO, sold 11,513 shares of MapLight Therapeutics, Inc. at $8.08 a share, worth $93K in total on Oct 15, 2026. Shares held after the trade: 198,597 (-5.5%).
MapLight Therapeutics CEO Christopher A. Kroeger Sells $595K of Stock
Christopher A. Kroeger, CEO, sold 73,691 shares of MapLight Therapeutics, Inc. at $8.08 a share, worth $595K in total on Oct 15, 2026. Shares held after the trade: 1,195,909 (-5.8%).
MapLight Therapeutics General Counsel Kristopher Hanson Sells $193K of Stock
Kristopher Hanson, General Counsel, sold 16,509 shares of MapLight Therapeutics, Inc. at $11.67 a share, worth $193K in total on Sep 16, 2026. Shares held after the trade: 137,044 (-10.8%).